SynthesisPathogens and global health
Mapping anti-diphtheria toxin antibody: a systematic review and meta-analysis with multi-level meta-regression.
Synthesis in Pathogens and global health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diphtheria is a reemerging vaccine-preventable infection of public health concern. Pooled estimates of serum IgG anti-diphtheria antibody levels can assist in estimating the susceptible population. The objective was to estimate pooled estimate of protective IgG anti-diphtheria antibodies in population globally. We searched three databases until May 2023. We included studies reporting serum anti-diphtheria antibody titre > 0.1 IU/ml as seroprotection. NHLBI checklist was used for quality assessment. Heterogeneity was explored and resolved by statistical methods. 1720 articles were retrieved out of which 51 articles were included. The pooled seropositivity rate against diphtheria was 57%. After removal of two influential outlier studies, pooled seropositivity became 51%. The meta-regression results for age depicted that seroprevalence significantly decreased with increasing age. Subgroup analysis done on basis of geographical distribution significantly reduced heterogeneity and revealed that the Western Pacific region and African regions had lower seroprotectivity compared to other regions. Subgrouping done based on year of sample collection revealed seroprotection was lower (55.63%) between 1986 and 2005 which increased to 67.11% between 2006 and 2015 and again dropped to 45.75% between 2016 and 2023. We concluded that after 2015, the disease has reemerged globally, with seroprotection level below 50% (45.75%) and overall only half of the population being seroprotected against diphtheria. So, there is a need for reinforcement of immunity against diphtheria (supplementary vaccination) after screening for antibody titre. PROSPERO registration number CRD42023458131.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.